Tags : (Rucaparib)

Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3

Shots: The P-III ARIEL3 study results involves assessing of Rubraca (rucaparib, 600mg, bid) vs PBO in 564 patients in a ratio (2:1) with platinum-sensitive recurrent ovarian cancer including patients with an epithelial ovarian, fallopian tube or primary peritoneal cancer The P-III ARIEL3 study results: IIT population & BRCA mutation, Mean QA-PFS in (12.02 vs 5.74 […]Read More

Alkermes Signs a Research Collaboration with Clovis Oncology to Evaluate

Shots: The companies enter into an agreement to jointly evaluate safety & efficacy of Alkermes’ ALKS 4230 in combination with Clovis Oncology’s Rucaparib & Lucitanib with equal cost sharing in preclinical studies, in patients with multiple tumors The focus of the agreement is for the onset of preclinical program for exploring anti-cancer effects of the […]Read More